NCT04197349View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

September 24, 2019

Primary Completion Date

August 19, 2020

Study Completion Date

August 19, 2020

Conditions
Migraine
Interventions
BIOLOGICAL

ALD1910

Single Dose IV infusion

BIOLOGICAL

Sumatriptan

Single dose subcutaneous injection

BIOLOGICAL

ALD1910

Single dose subcutaneous injection

Trial Locations (1)

Unknown

Nucleus Network Pty Ltd, Melbourne

Sponsors
All Listed Sponsors
collaborator

Alder Biopharmaceuticals, Inc.

INDUSTRY

lead

H. Lundbeck A/S

INDUSTRY

NCT04197349 - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman | Biotech Hunter | Biotech Hunter